Overview

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Acenocoumarol for the first time, the occurrence of intracranial haemorrhage, gastrointestinal and urogenital bleeding, and the occurrence of non-infective liver disease.
Details
Lead Sponsor:
Bayer
Collaborator:
Janssen Scientific Affairs, LLC
Treatments:
Rivaroxaban